PMID- 28594977 OWN - NLM STAT- MEDLINE DCOM- 20170809 LR - 20220316 IS - 2168-6173 (Electronic) IS - 2168-6165 (Print) IS - 2168-6165 (Linking) VI - 135 IP - 7 DP - 2017 Jul 1 TI - Association of Glaucoma-Related, Optical Coherence Tomography-Measured Macular Damage With Vision-Related Quality of Life. PG - 783-788 LID - 10.1001/jamaophthalmol.2017.1659 [doi] AB - IMPORTANCE: Little is known about the association between structural macular damage and self-reported visual function of people with glaucoma. OBJECTIVE: To determine the association between vision-related quality of life among patients with primary open-angle glaucoma with structural macular retinal ganglion cell plus inner plexiform layer (RGC+IPL) loss identified by spectral-domain optical coherence tomography (SD-OCT) machine-generated deviation maps and thickness measurements. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional prospective study was conducted from March 1, 2014, to March 30, 2015, at the Department of Ophthalmology at Columbia University Medical Center. The participants were 107 patients who were enrolled in the study and represented the entire range of glaucomatous damage. All 214 eyes of the 107 participants underwent 10-2 visual field tests and SD-OCT scans, and all participants completed the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25). They also received ophthalmologic examination, including medical history review, best-corrected visual acuity, slitlamp biomicroscopy, intraocular pressure measurement, gonioscopy, dilated ophthalmoscopy, and standard automated perimetry. Macular RGC+IPL loss was determined by diffuse or focal patterns on SD-OCT-generated deviation maps (probability map that compared patients with aged-matched normative database) and thickness measurements. MAIN OUTCOMES AND MEASURES: Regression analyses to assess the association of NEI VFQ-25 scores (score range: 41.9-99.5; higher scores indicate better functioning) with patterns of RGC+IPL loss and with RGC+IPL thickness measurements. RESULTS: Of the 107 patients, 48 (45%) were men and the mean (SD) age was 65 (11) years. The self-reported race/ethnicity of participants consisted of 45 (46%) black, 47 (48%) white, and 6 (6%) "other" individuals. In the univariable analyses, patients with diffuse macular RGC+IPL loss had mean composite Rasch-calibrated NEI VFQ-25 scores that were 6.15 points lower than the scores of patients with focal damage (beta = -6.15; 95% CI, -11.7 to -0.59; P = .03). The effect remained significant even after controlling for mean RGC+IPL thickness (beta = -7.64; 95% CI, -14.2 to -1.03; P = .02). CONCLUSIONS AND RELEVANCE: Characteristic patterns of glaucoma-related macular RGC+IPL loss appeared to be more important predictors of vision-related quality of life than thickness measures, with diffuse RGC+IPL loss as an indicator for diminished vision-related quality of life. FAU - Prager, Alisa J AU - Prager AJ AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. FAU - Hood, Donald C AU - Hood DC AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York2Department of Psychology, Columbia University, New York, New York. FAU - Liebmann, Jeffrey M AU - Liebmann JM AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. FAU - De Moraes, C Gustavo AU - De Moraes CG AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. FAU - Al-Aswad, Lama A AU - Al-Aswad LA AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. FAU - Yu, Qi AU - Yu Q AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. FAU - Cioffi, George A AU - Cioffi GA AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. FAU - Blumberg, Dana M AU - Blumberg DM AD - Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York. LA - eng GR - R01 EY002115/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA Ophthalmol JT - JAMA ophthalmology JID - 101589539 SB - IM CIN - JAMA Ophthalmol. 2017 Jul 1;135(7):789-790. PMID: 28594985 MH - Aged MH - Cross-Sectional Studies MH - Female MH - Follow-Up Studies MH - Glaucoma/*diagnosis/physiopathology/psychology MH - Humans MH - Macula Lutea/*pathology MH - Male MH - Prospective Studies MH - *Quality of Life MH - Retinal Ganglion Cells/*pathology MH - Surveys and Questionnaires MH - Tomography, Optical Coherence/*methods MH - *Visual Acuity MH - Visual Field Tests MH - Visual Fields/*physiology PMC - PMC5710204 COIS- Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Hood reported receiving equipment and financial support from Topcon as well as equipment from Heidelberg. Dr Liebmann reported being a consultant to Carl Zeiss Meditec, Inc on matters unrelated to this study. No other disclosures were reported. EDAT- 2017/06/09 06:00 MHDA- 2017/08/10 06:00 PMCR- 2018/07/13 CRDT- 2017/06/09 06:00 PHST- 2017/06/09 06:00 [pubmed] PHST- 2017/08/10 06:00 [medline] PHST- 2017/06/09 06:00 [entrez] PHST- 2018/07/13 00:00 [pmc-release] AID - 2630817 [pii] AID - eoi170047 [pii] AID - 10.1001/jamaophthalmol.2017.1659 [doi] PST - ppublish SO - JAMA Ophthalmol. 2017 Jul 1;135(7):783-788. doi: 10.1001/jamaophthalmol.2017.1659.